Cargando…
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p
BACKGROUND & AIMS: Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory mechanism(s) involved in A3B induction and related HBV control. METHODS: Di...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523871/ https://www.ncbi.nlm.nih.gov/pubmed/34704004 http://dx.doi.org/10.1016/j.jhepr.2021.100354 |
_version_ | 1784585386867032064 |
---|---|
author | Faure-Dupuy, Suzanne Riedl, Tobias Rolland, Maude Hizir, Zoheir Reisinger, Florian Neuhaus, Katharina Schuehle, Svenja Remouchamps, Caroline Gillet, Nicolas Schönung, Maximilian Stadler, Mira Wettengel, Jochen Barnault, Romain Parent, Romain Schuster, Linda Christina Farhat, Rayan Prokosch, Sandra Leuchtenberger, Corinna Öllinger, Rupert Engleitner, Thomas Rippe, Karsten Rad, Roland Unger, Kristian Tscharahganeh, Darjus Lipka, Daniel B. Protzer, Ulrike Durantel, David Lucifora, Julie Dejardin, Emmanuel Heikenwälder, Mathias |
author_facet | Faure-Dupuy, Suzanne Riedl, Tobias Rolland, Maude Hizir, Zoheir Reisinger, Florian Neuhaus, Katharina Schuehle, Svenja Remouchamps, Caroline Gillet, Nicolas Schönung, Maximilian Stadler, Mira Wettengel, Jochen Barnault, Romain Parent, Romain Schuster, Linda Christina Farhat, Rayan Prokosch, Sandra Leuchtenberger, Corinna Öllinger, Rupert Engleitner, Thomas Rippe, Karsten Rad, Roland Unger, Kristian Tscharahganeh, Darjus Lipka, Daniel B. Protzer, Ulrike Durantel, David Lucifora, Julie Dejardin, Emmanuel Heikenwälder, Mathias |
author_sort | Faure-Dupuy, Suzanne |
collection | PubMed |
description | BACKGROUND & AIMS: Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory mechanism(s) involved in A3B induction and related HBV control. METHODS: Differentiated HepaRG cells (dHepaRG) knocked-down for NF-κB signalling components, transfected with siRNA or micro RNAs (miRNA), and primary human hepatocytes ± HBV or HBVΔX or HBV-RFP, were treated with lymphotoxin beta receptor (LTβR)-agonist (BS1). The biological outcomes were analysed by reverse transcriptase-qPCR, immunoblotting, luciferase activity, chromatin immune precipitation, electrophoretic mobility-shift assay, targeted-bisulfite-, miRNA-, RNA-, genome-sequencing, and mass-spectrometry. RESULTS: We found that canonical and non-canonical NF-κB signalling pathways are mandatory for A3B induction and anti-HBV effects. The degree of immune-mediated A3B production is independent of A3B promoter demethylation but is controlled post-transcriptionally by the miRNA 138-5p expression (hsa-miR-138-5p), promoting A3B mRNA decay. Hsa-miR-138-5p over-expression reduced A3B levels and its antiviral effects. Of note, established infection inhibited BS1-induced A3B expression through epigenetic modulation of A3B promoter. Twelve days of treatment with a LTβR-specific agonist BS1 is sufficient to reduce the cccDNA pool by 80% without inducing significant damages to a subset of cancer-related host genes. Interestingly, the A3B-mediated effect on HBV is independent of the transcriptional activity of cccDNA as well as on rcDNA synthesis. CONCLUSIONS: Altogether, A3B represents the only described enzyme to target both transcriptionally active and inactive cccDNA. Thus, inhibiting hsa-miR-138-5p expression should be considered in the combinatorial design of new therapies against HBV, especially in the context of immune-mediated A3B induction. LAY SUMMARY: Immune-mediated induction of cytidine deaminase APOBEC3B is transcriptionally regulated by NF-κB signalling and post-transcriptionally downregulated by hsa-miR-138-5p expression, leading to cccDNA decay. Timely controlled APOBEC3B-mediated cccDNA decay occurs independently of cccDNA transcriptional activity and without damage to a subset of cancer-related genes. Thus, APOBEC3B-mediated cccDNA decay could offer an efficient therapeutic alternative to target hepatitis B virus chronic infection. |
format | Online Article Text |
id | pubmed-8523871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-85238712021-10-25 Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p Faure-Dupuy, Suzanne Riedl, Tobias Rolland, Maude Hizir, Zoheir Reisinger, Florian Neuhaus, Katharina Schuehle, Svenja Remouchamps, Caroline Gillet, Nicolas Schönung, Maximilian Stadler, Mira Wettengel, Jochen Barnault, Romain Parent, Romain Schuster, Linda Christina Farhat, Rayan Prokosch, Sandra Leuchtenberger, Corinna Öllinger, Rupert Engleitner, Thomas Rippe, Karsten Rad, Roland Unger, Kristian Tscharahganeh, Darjus Lipka, Daniel B. Protzer, Ulrike Durantel, David Lucifora, Julie Dejardin, Emmanuel Heikenwälder, Mathias JHEP Rep Research Article BACKGROUND & AIMS: Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory mechanism(s) involved in A3B induction and related HBV control. METHODS: Differentiated HepaRG cells (dHepaRG) knocked-down for NF-κB signalling components, transfected with siRNA or micro RNAs (miRNA), and primary human hepatocytes ± HBV or HBVΔX or HBV-RFP, were treated with lymphotoxin beta receptor (LTβR)-agonist (BS1). The biological outcomes were analysed by reverse transcriptase-qPCR, immunoblotting, luciferase activity, chromatin immune precipitation, electrophoretic mobility-shift assay, targeted-bisulfite-, miRNA-, RNA-, genome-sequencing, and mass-spectrometry. RESULTS: We found that canonical and non-canonical NF-κB signalling pathways are mandatory for A3B induction and anti-HBV effects. The degree of immune-mediated A3B production is independent of A3B promoter demethylation but is controlled post-transcriptionally by the miRNA 138-5p expression (hsa-miR-138-5p), promoting A3B mRNA decay. Hsa-miR-138-5p over-expression reduced A3B levels and its antiviral effects. Of note, established infection inhibited BS1-induced A3B expression through epigenetic modulation of A3B promoter. Twelve days of treatment with a LTβR-specific agonist BS1 is sufficient to reduce the cccDNA pool by 80% without inducing significant damages to a subset of cancer-related host genes. Interestingly, the A3B-mediated effect on HBV is independent of the transcriptional activity of cccDNA as well as on rcDNA synthesis. CONCLUSIONS: Altogether, A3B represents the only described enzyme to target both transcriptionally active and inactive cccDNA. Thus, inhibiting hsa-miR-138-5p expression should be considered in the combinatorial design of new therapies against HBV, especially in the context of immune-mediated A3B induction. LAY SUMMARY: Immune-mediated induction of cytidine deaminase APOBEC3B is transcriptionally regulated by NF-κB signalling and post-transcriptionally downregulated by hsa-miR-138-5p expression, leading to cccDNA decay. Timely controlled APOBEC3B-mediated cccDNA decay occurs independently of cccDNA transcriptional activity and without damage to a subset of cancer-related genes. Thus, APOBEC3B-mediated cccDNA decay could offer an efficient therapeutic alternative to target hepatitis B virus chronic infection. Elsevier 2021-08-25 /pmc/articles/PMC8523871/ /pubmed/34704004 http://dx.doi.org/10.1016/j.jhepr.2021.100354 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Faure-Dupuy, Suzanne Riedl, Tobias Rolland, Maude Hizir, Zoheir Reisinger, Florian Neuhaus, Katharina Schuehle, Svenja Remouchamps, Caroline Gillet, Nicolas Schönung, Maximilian Stadler, Mira Wettengel, Jochen Barnault, Romain Parent, Romain Schuster, Linda Christina Farhat, Rayan Prokosch, Sandra Leuchtenberger, Corinna Öllinger, Rupert Engleitner, Thomas Rippe, Karsten Rad, Roland Unger, Kristian Tscharahganeh, Darjus Lipka, Daniel B. Protzer, Ulrike Durantel, David Lucifora, Julie Dejardin, Emmanuel Heikenwälder, Mathias Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p |
title | Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p |
title_full | Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p |
title_fullStr | Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p |
title_full_unstemmed | Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p |
title_short | Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p |
title_sort | control of apobec3b induction and cccdna decay by nf-κb and mir-138-5p |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523871/ https://www.ncbi.nlm.nih.gov/pubmed/34704004 http://dx.doi.org/10.1016/j.jhepr.2021.100354 |
work_keys_str_mv | AT fauredupuysuzanne controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT riedltobias controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT rollandmaude controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT hizirzoheir controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT reisingerflorian controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT neuhauskatharina controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT schuehlesvenja controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT remouchampscaroline controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT gilletnicolas controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT schonungmaximilian controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT stadlermira controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT wettengeljochen controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT barnaultromain controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT parentromain controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT schusterlindachristina controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT farhatrayan controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT prokoschsandra controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT leuchtenbergercorinna controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT ollingerrupert controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT engleitnerthomas controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT rippekarsten controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT radroland controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT ungerkristian controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT tscharahganehdarjus controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT lipkadanielb controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT protzerulrike controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT duranteldavid controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT luciforajulie controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT dejardinemmanuel controlofapobec3binductionandcccdnadecaybynfkbandmir1385p AT heikenwaldermathias controlofapobec3binductionandcccdnadecaybynfkbandmir1385p |